Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment:  The TAILORx Trial

This research study is for women with early-stage breast cancer that measures 1.1-5.0 cm, is ER/PR positive, node negative and HER2 negative.  The purpose of this study is to find out if a new test (Oncotype DX) will be able to help doctors and their patients with early breast cancer make better treatment decisions.  Patients will receive either hormonal therapy, or hormonal and chemotherapy, depending on their Recurrence Score determined by the Oncotype DX assay.  The exact treatment or regimen will be decided by the doctor and the patient.